A tumor is not merely a mass of cancer cells, but a dynamically evolving, aberrant system. This system is co-constructed by malignant cells and various host components, including immune cells, cancer-associated fibroblasts (CAFs), abnormal blood vessels, the extracellular matrix, and a complex network of signaling molecules. Far from being a passive backdrop, the TME plays a decisive role through continuous reciprocal interactions, driving critical malignant processes such as tumor growth, invasion, metastasis, therapy resistance, and immune evasion. Consequently, cutting-edge research is focused on deciphering these intricate interaction networks. The ultimate goal is to develop novel therapeutic strategies that can target or reprogram the TME, thereby synergizing with and enhancing the efficacy of conventional therapies and immunotherapies.
The evolution of 3D culture systems has led to the development of sophisticated organoid models. These advanced platforms are specifically engineered to dissect the dynamic crosstalk between neoplastic cells and their surrounding microenvironment, providing a more physiologically relevant context for mechanistic studies and therapeutic screening.
These systems integrate organoids into a controlled, perfusable microenvironment. They introduce dynamic fluid flow and mechanical forces, enabling the modeling of key processes such as vascular perfusion, intravasation, and metastasis, as well as the study of drug responses under conditions that mimic physiological circulation.
Utilizing 3D bioprinting, this technique enables the precise spatial patterning of cancer cells, stromal components, and matrix materials into defined architectures. This facilitates the study of how specific tissue geometry, cellular organization, and engineered extracellular matrix properties influence tumor progression and treatment efficacy.
Tumor Organoid Co-culture Models
These systems involve the integration of specific stromal cell types, such as immune cells, fibroblasts, or endothelial cells, with tumor organoids. These models are designed to recapitulate essential cell-cell and paracrine signaling, providing a platform to dissect mechanisms of immune evasion, stromal-mediated therapy resistance, and angiogenic signaling.
Cancer organoids model key architectural and functional features of native tumors, serving as a powerful platform for TME research. These 3D models, derived from various cellular sources, enable the investigation of cell-cell and cell-matrix interactions in a controlled yet physiologically relevant context.
By integrating deep expertise in diverse 3D cancer models with state-of-the-art analytical technologies, Alfa Cytology delivers robust, high-fidelity data. Our strength lies in customizing every aspect of the study, from selecting the most appropriate organoid platform and matrix composition to defining assay endpoints, ensuring the experimental system aligns precisely with your research objectives. We provide a seamless, collaborative partnership to accelerate your TME research from concept to reliable data.
Alfa Cytology's services support tumor biology and microenvironment research by developing and utilizing a comprehensive spectrum of cancer organoid models. This includes systems derived from multiple cellular sources. Our capabilities encompass various 3D culture paradigms tailored to mimic specific TME interactions, ensuring the selection of the biologically relevant model for each investigation.
By Disease
By Sources
To address the multifaceted nature of tumor-stroma interactions, we offer a suite of in-depth analytical services designed for testing within complex 3D models. Our approaches integrate physiological culture conditions with advanced readout technologies to dissect specific mechanistic drivers of cancer progression and therapy resistance.
Extracellular Matrix and Tumor Dynamics
Focused on the bi-directional interaction between tumor cells and their structural niche. In-depth analysis of extracellular matrix (ECM) composition, stiffness, and remodeling using proteomic assays and biomechanical testing. We employ live-cell imaging to track cancer cell migration, matrix deformation, and protease activity in real-time within 3D matrices.
Angiogenesis and Lymphangiogenesis Analysis
Dedicated to modeling and quantifying tumor-induced vascular recruitment. Functional assessment of tube formation and sprouting using endothelial cell co-culture assays. Quantification of key mediators (VEGF, Angiopoietins) via multiplex immunoassays and evaluation of lymphatic vessel density and patterning in organoid-stroma models.
Tumorigenesis and Metastasis Analysis
Targeting the fundamental processes of cancer spread. Longitudinal tracking of clonal evolution and subpopulation dynamics via sequencing. Functional assays for adhesion, invasion through defined barriers, and assessment of circulating tumor cell (CTC) properties. Analysis of key pathways (Wnt, Hedgehog, Notch) and EMT markers.
Cancer Progression and Metabolic Analysis
Investigating the reprogrammed metabolism that fuels tumor growth and influences the TME. Profiling of metabolic adaptations (glycolysis, oxidative phosphorylation, fatty acid oxidation) using advanced technology and metabolomics. Investigation of nutrient competition and metabolic crosstalk within the TME using isotope tracing and co-culture systems.
A comprehensive understanding of the TME requires a multi-parametric analytical strategy that captures molecular, cellular, and functional phenotypes. Our assay portfolio is curated to deliver insights from your 3D organoid models.
Molecular Profiling and Spatial Characterization
Genomic and transcriptomic analyses to deconvolute cellular heterogeneity and identify drivers within the TME. Spatial context is interrogated through multiplex immunofluorescence (and spatial transcriptomics upon request), mapping the localization of cell types and signaling pathways in 3D organoid architectures.
Protein & Secretory Factor Analysis
A comprehensive suite of proteomic and secretome profiling techniques is employed. This includes quantitative proteomics to assess signaling network states, alongside high-plex multiplex immunoassays to quantitatively profile the dynamic secretion of cytokines, chemokines, growth factors, and proteases.
Cellular & Functional Phenotyping
Functional live-cell and endpoint assays quantify critical tumor behaviors. These include high-content 3D confocal imaging for invasion, morphology, and proliferation; real-time metabolic flux analysis to profile glycolysis and oxidative phosphorylation; and flow cytometry for detailed surface marker and intracellular target expression. Apoptosis, cell cycle, and viability are precisely measured.
Microenvironment-Specific Interaction Assays
Specialized assays are designed to dissect specific TME interactions. These include stromal co-culture assays with readouts for angiogenesis, immune-mediated killing, or fibroblast activation; analysis of ECM remodeling and degradation; and the use of microfluidic platforms to model perfusion, vascular recruitment, and metastatic seeding in a controlled, physiologically relevant context.
Alfa Cytology established a model in which patient-derived prostate cancer organoids were treated with conditioned medium from cancer-associated fibroblasts (CAF-CM) to investigate paracrine-mediated therapy resistance. This study aimed to elucidate how stromal-secreted factors contribute to treatment failure in advanced disease. Organoids were cultured in CAF-CM and treated with therapeutic agents under controlled conditions, with viability and growth dynamics monitored. Analysis revealed that CAF-CM conferred a significant protective effect, enhancing the resistance of organoids to the therapeutic. Subsequent investigation identified a key paracrine signaling axis activated in the co-culture model as a critical mediator of this resistance. Importantly, targeted inhibition of this pathway within the organoid platform successfully re-sensitized the tumor cells to treatment. These results demonstrated how our advanced organoid co-culture services can identify novel mechanisms of stromal-driven resistance in a clinically relevant model.
Fig.1 CAF-derived secreted factors confer resistance to antiandrogen therapy. (A) Growth of prostate cancer organoids in DHT-deficient organoid media supplemented with CAF-CM. (B) Growth of prostate cancer PDOs in drug or vehicle control containing organoid media supplemented with CAF-CM. Data are presented as mean ± SEM (n=5; **p < 0.01, ***p < 0.001).
Unlocking the complexities of the tumor microenvironment requires sophisticated, physiologically relevant models and multidimensional analysis. Alfa Cytology's dedicated tumor biology and microenvironment research services provide access to a versatile portfolio of advanced platforms and the necessary expertise to advance your oncology programs. Contact our scientific team to discuss how we can customize a project to meet your specific objectives and accelerate your discoveries.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.